Fate Therapeutics (FATE) Competitors $1.15 -0.01 (-0.86%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.14 0.00 (-0.43%) As of 07/11/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FATE vs. SEPN, SIGA, ATYR, PGEN, MREO, CAPR, KMDA, RAPP, CGEM, and PRTCShould you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include Septerna (SEPN), Siga Technologies (SIGA), aTyr Pharma (ATYR), Precigen (PGEN), Mereo BioPharma Group (MREO), Capricor Therapeutics (CAPR), Kamada (KMDA), Rapport Therapeutics (RAPP), Cullinan Therapeutics (CGEM), and PureTech Health (PRTC). These companies are all part of the "pharmaceutical products" industry. Fate Therapeutics vs. Its Competitors Septerna Siga Technologies aTyr Pharma Precigen Mereo BioPharma Group Capricor Therapeutics Kamada Rapport Therapeutics Cullinan Therapeutics PureTech Health Fate Therapeutics (NASDAQ:FATE) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings. Do analysts rate FATE or SEPN? Fate Therapeutics currently has a consensus price target of $3.83, indicating a potential upside of 233.33%. Septerna has a consensus price target of $26.75, indicating a potential upside of 128.05%. Given Fate Therapeutics' higher possible upside, research analysts plainly believe Fate Therapeutics is more favorable than Septerna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13Septerna 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Do institutionals & insiders have more ownership in FATE or SEPN? 97.5% of Fate Therapeutics shares are held by institutional investors. 5.5% of Fate Therapeutics shares are held by company insiders. Comparatively, 4.3% of Septerna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is FATE or SEPN more profitable? Septerna has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,318.93%. Septerna's return on equity of 0.00% beat Fate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Fate Therapeutics-1,318.93% -47.17% -34.60% Septerna N/A N/A N/A Does the media prefer FATE or SEPN? In the previous week, Fate Therapeutics and Fate Therapeutics both had 4 articles in the media. Fate Therapeutics' average media sentiment score of 0.98 beat Septerna's score of 0.63 indicating that Fate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Septerna 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, FATE or SEPN? Septerna has lower revenue, but higher earnings than Fate Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFate Therapeutics$13.63M9.67-$186.26M-$1.49-0.77Septerna$1.08M483.97-$71.80MN/AN/A SummarySepterna beats Fate Therapeutics on 7 of the 12 factors compared between the two stocks. Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FATE vs. The Competition Export to ExcelMetricFate TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$132.94M$2.99B$5.61B$9.11BDividend YieldN/A2.39%5.24%4.02%P/E Ratio-0.7720.5827.9620.25Price / Sales9.67292.00430.8999.65Price / CashN/A42.8637.4658.16Price / Book0.417.638.045.49Net Income-$186.26M-$55.05M$3.18B$250.27M7 Day Performance0.44%8.54%3.67%4.80%1 Month Performance-17.86%5.51%4.09%7.68%1 Year Performance-68.14%2.03%29.58%16.36% Fate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FATEFate Therapeutics3.6114 of 5 stars$1.15-0.9%$3.83+233.3%-66.2%$132.94M$13.63M-0.77550Gap UpSEPNSepterna1.5403 of 5 stars$10.85-4.6%$26.75+146.5%N/A$483.45M$977K0.00N/ANews CoverageSIGASiga Technologies2.2221 of 5 stars$6.73+0.6%N/A-22.1%$480.80M$120.33M10.0440News CoverageOptions VolumeATYRaTyr Pharma2.0911 of 5 stars$5.30-0.2%$20.20+281.1%N/A$471.72MN/A-6.5453Gap UpHigh Trading VolumePGENPrecigen4.1195 of 5 stars$1.59-1.9%$6.00+277.4%+11.6%$469.34M$3.92M-2.84190Positive NewsAnalyst UpgradeMREOMereo BioPharma Group1.5669 of 5 stars$2.92+1.7%$7.60+160.3%-58.6%$464.28M$10M-41.7140News CoverageAnalyst ForecastGap UpHigh Trading VolumeCAPRCapricor Therapeutics2.5348 of 5 stars$9.90-3.4%$32.22+225.5%+66.4%$452.23M$22.27M-6.97101Trending NewsAnalyst ForecastGap DownKMDAKamada3.9398 of 5 stars$7.71-2.2%$13.00+68.6%+24.0%$443.40M$160.95M26.59360Positive NewsRAPPRapport Therapeutics1.8753 of 5 stars$12.04flat$28.00+132.6%-43.6%$439.44MN/A-3.49N/ANews CoverageAnalyst ForecastCGEMCullinan Therapeutics1.572 of 5 stars$7.42-5.0%$30.00+304.3%-52.4%$437.89MN/A-2.5530News CoveragePositive NewsGap UpPRTCPureTech Health2.4891 of 5 stars$18.01flat$45.00+149.9%-25.4%$432.60M$4.83M0.00100News Coverage Related Companies and Tools Related Companies Septerna Alternatives Siga Technologies Alternatives aTyr Pharma Alternatives Precigen Alternatives Mereo BioPharma Group Alternatives Capricor Therapeutics Alternatives Kamada Alternatives Rapport Therapeutics Alternatives Cullinan Therapeutics Alternatives PureTech Health Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FATE) was last updated on 7/12/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FATE Stock Alerts